Phase 2 and 3 clinical trials in NSCLC evaluating concurrent platinum-based chemotherapy with RT and PD-L1 blockade reported an incidence of about 30% in adverse related events [27, 34]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.